Temporal bone squamous cell carcinoma (TBSCC) has a poor prognosis and the study aimed to evaluate 5-year survival rates for advanced cases across various treatment methods.
A total of 1229 studies were reviewed, resulting in 31 that provided relevant survival data, analyzing 1289 patients, which showed a 5-year overall survival (OS) rate of 59.6%.
The findings indicated no significant differences in survival rates between different treatments for early and advanced-stage cancers, suggesting similar outcomes regardless of the treatment approach used.